Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 274-778-7 | CAS number: 70693-62-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Epidemiological data
Administrative data
- Endpoint:
- epidemiological data
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2013-2016
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 016
- Report date:
- 2016
Materials and methods
- Study type:
- cross sectional study
- Endpoint addressed:
- respiratory sensitisation
Test guideline
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- - Principle of test:
Active employees (as of January 1st, 2016) at the Oxone™ facility, Memphis site, were identified from the Chemours Epidemiology Registry. The most recent responses to Interval Health History and Wellness Appraisal (IHWA) questionnaire from these employees were obtained from Medgate (an internal health electronic recording system). The IHWA questionnaire was administered by the Chemours Global Health Services (GHS) staff every three years to assess the current physical health status of the employees (Attachment 1 in "attached background material"). For those employees who are participated in the fire brigades, the same questionnaire is administered annually. Of the 28 yes/no questions of the IHWA questionnaire, 3 questions are designed to assess the current respiratory health: (1) frequent cough, chest congestion or wheezing; (2) a chronic respiratory condition such as bronchitis or emphysema; and (3) recurring nasal and/or sinus congestion.
Recently hired employees do not fill out the IHWA questionnaire, but instead they fill out the OSHA Respirator Medical Evaluation Questionnaire (OSHA questionnaire, Attachment 2 in "attached background material"). Questions 3 (a to l), 4 (a to n), and 7a of Part A and Section 2 of the OSHA questionnaire are designed to assess the current respiratory health. Health information obtained from the OSHA questionnaire also served as the health baseline of the employee. This applies to a small number of these employees.
In addition to respiratory health questionnaires, pulmonary function test (PFT) results were also evaluated for potential airway obstruction. As part of the medical surveillance program, GHS staff who have completed a NIOSH-approved pulmonary function testing course or equivalent administer the test to all required employees every three years at the minimum. The spirometric criterion from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) was used for the diagnosis of chronic obstructive pulmonary disease (COPD) (GOLD 2016). COPD is defined as the ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) less than 0.7 (or <70%).
A summary of responses for the current respiratory health from both the IHWA and OSHA questionnaires, and PFT results are compiled to evaluate for any potential pulmonary symptoms among these employees. - GLP compliance:
- not specified
Test material
- Reference substance name:
- Pentapotassium bis(peroxymonosulphate) bis(sulphate)
- EC Number:
- 274-778-7
- EC Name:
- Pentapotassium bis(peroxymonosulphate) bis(sulphate)
- Cas Number:
- 70693-62-8
- Molecular formula:
- H3K5O18S4
- IUPAC Name:
- pentapotassium bis((hydroperoxysulfonyl)oxidanide) hydrogen sulfate sulfate
- Test material form:
- solid
Constituent 1
Method
- Type of population:
- occupational
- Ethical approval:
- not applicable
- Details on study design:
- METHOD OF DATA COLLECTION
- Type: Questionnaire, pulmonary function test (PFT)
STUDY PERIOD: 2013-2016
SETTING: Oxone™ facility, Memphis site
STUDY POPULATION
- Selection criteria: active employees
- Total number of subjects participating in study: 33, 6 of them were newly hired
- Sex/age/race: 6 females, 27 males, mean 44 years (min: 25, max: 68)
- 30 of the employees worked in production and maintenance, 1 in supply chain management, 2 in training
HEALTH EFFECTS STUDIED
- IHWA-questionnaire: frequent cough, chest congestion or wheezing chronic respiratory condition such as bronchitis or emphysema, recurring nasal and/or sinus congestion
- OSHA-questionnaire: pulmonary or lung problems/illnesses, medication
- Diagnostic procedure: Questionnaire and pulmonary function test (PFT) results - Exposure assessment:
- not specified
Results and discussion
- Results:
- FINDINGS
Among those employees who filled out an IHWA questionnaire, none had reported frequent cough, chest congestion or wheezing, as well as a chronic respiratory condition such as bronchitis or emphysema. Of these, 6 employees reported of having recurring nasal and/or sinus congestion but five of them attributed the symptoms to seasonal and year-round allergies, and one employee attributed the sneezing to dust in the area. The individual employee who reported of having sneezing was part of the fire brigades, and had been filling out the IHWA questionnaire annually. For the 2014 calendar year, this same individual employee did not report having any recurring nasal and/or sinus congestion. Among those 6 newly hired employees who filled out the OSHA questionnaire, which consisted of 27 health factors describing the conditions or symptoms of pulmonary or lung illness, only one employee reported of having mild asthma which flares up with colds. This individual employee with mild asthma at baseline health passed the pulmonary function test, and is medically able to use any respirator.
The results of the pulmonary function test showed that no COPD was observed among the employees from 2013 to 2016 calendar year.
Any other information on results incl. tables
Table 1: Pulmonary function test (PFT) results
Spirometric indices | N | Mean | Max | 75th | Median | 25th | Min |
FEV1 (% predicted) | 33 | 91 | 121 | 98 | 91 | 85 | 70 |
FVC (% predicted) | 33 | 93 | 113 | 102 | 92 | 85 | 74 |
FEV1/FVC (%) | 33 | 97 | 109 | 104 | 99 | 93 | 79 |
Applicant's summary and conclusion
- Conclusions:
- Results obtained from both the IHWA and OSHA questionnaires, and PFT among current active employees who are associated with the Oxone™ manufacturing facility at Memphis site indicated that there were no pulmonary symptoms reported among the employees for the 2013-2016 calendar year.
- Executive summary:
33 active employees (as of January 1st, 2016) at the Oxone™ facility, Memphis site, filled out a questionnaire to assess their current physical health status. Of the 28 yes/no questions of the IHWA (Interval Health History and Wellness Appraisal ) questionnaire, 3 questions were designed to assess the current respiratory health. Recently hired employees did not fill out the IHWA questionnaire, but instead they filled out the OSHA Respirator Medical Evaluation Questionnaire. In addition to the respiratory health questionnaires, pulmonary function test (PFT) results were also evaluated for potential airway obstruction.
Among those employees who filled out an IHWA questionnaire, none had reported frequent cough, chest congestion or wheezing, as well as a chronic respiratory condition such as bronchitis or emphysema. Of these, 6 employees reported of having recurring nasal and/or sinus congestion but five of them attributed the symptoms to seasonal and year-round allergies, and one employee attributed the sneezing to dust in the area. The individual employee who reported of having sneezing was part of the fire brigades, and had been filling out the IHWA questionnaire annually. For the 2014 calendar year, this same individual employee did not report having any recurring nasal and/or sinus congestion.
Among those 6 newly hired employees who filled out the OSHA questionnaire, which consisted of 27 health factors describing the conditions or symptoms of pulmonary or lung illness, only one employee reported of having mild asthma which flares up with colds. This individual employee with mild asthma at baseline health passed the pulmonary function test, and is medically able to use any respirator.
The PFT results indicated that there were no pulmonary symptoms reported among the employees for the 2013-2016 calendar year.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.